Lower sales due to the pandemic but new rights issue secures continued international expansion

First quarter                  · Net sales reached SEK 17.0 (26.8) million. · Result after tax came in at SEK -8.9 (0.7) million. · Earnings per share, basic and diluted, were SEK -0.06 (0.01). · Cash and cash equivalents were SEK 21.4 (33.9) million. Significant events in Q1 · Enzymatica’s sales during the quarter declined compared with the corresponding period in 2020 due to the effects of the pandemic, which essentially reduced the cold remedy market by 50 percent, both in Sweden and in other markets.  · Enzymatica announced on March 22 that sales for 2021